|1.||Tralau, Tewes: 1 article (10/2007)|
|2.||Campbell, Barry J: 1 article (10/2007)|
|3.||Vuilleumier, Stéphane: 1 article (10/2007)|
|4.||Thibault, Christelle: 1 article (10/2007)|
|5.||Hart, C Anthony: 1 article (10/2007)|
|6.||Kertesz, Michael A: 1 article (10/2007)|
|1.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
|2.||Dental Caries (White Spot)
|3.||Cystic Fibrosis (Mucoviscidosis)
|4.||Crohn Disease (Crohn's Disease)
04/01/1995 - "Longitudinal studies in patients with ulcerative colitis show fluctuations of faecal mucin sulphatase activity corresponding to clinical disease activity in six of seven patients. "
04/01/1995 - "Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment."
04/01/1995 - "The increased faecal mucin sulphatase activity in ulcerative colitis could be the result of greater intraluminal substrate (mucin) availability leading to bacterial enzyme induction, but would probably result in more rapid degradation of secreted mucin and represents a potential target for treatment."
04/01/1995 - "Faecal mucin sulphatase activity assayed using 35S mucin as substrate was increased in ulcerative colitis (median 80.2 units/g pellet weight (range 6.9-1063; 95% confidence intervals (CI): 45.2 to 293.8, n = 22) compared with 11.3 units/g (range 3.0-53.5; 95% CI: 8.7 to 29.8, n = 17) in healthy controls (p < 0.01), where one unit released 1000 dpm free sulphate/hour from 35S mucin (1680 dpm/microgram). "